[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556326":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":18,"responsibleParty":76,"collaborators":7,"id":78,"slug":79,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":7,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":7,"enrollmentInfo":87,"targetDuration":7,"studyType":90,"phases":7,"briefSummary":91,"conditions":92,"keywords":7,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Kazakhstan Scientific Society for Study of intestine diseases","OTHER",null,[9,14],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Kanat Khazhidinov","CONTACT","+7 707 413 8263","kanat.khazhidinov@smo-mera.kz",{"name":15,"role":11,"phone":16,"phoneExt":7,"email":17},"Yekaterina Sakhabutdinova","+7 707 375 8530","yekaterina.sakhabutdinova@smo-mera.kz",[19,36,50,63],{"facility":20,"status":21,"city":22,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":25,"geoPoint":30,"contacts":31},"NJSC \"West Kazakhstan Marat Ospanov Medical University\"","RECRUITING","Aktobe","Kazakhstan","KZ",{"type":26,"coordinates":27},"Point",[28,29],57.20718,50.27969,{"lat":29,"lon":28},[32],{"name":33,"role":11,"phone":34,"phoneExt":7,"email":35},"Aset Kaliev","+7 (7132) 563425","info@.zkmu.kz",{"facility":37,"status":21,"city":38,"state":7,"zip":39,"country":23,"countryCode":24,"cosmosGeoPoint":40,"geoPoint":44,"contacts":45},"Non-Profit Joint Stock Company \"Kazakh National Medical University named after S.D. Asfendiyarov\"","Almaty","055990",{"type":26,"coordinates":41},[42,43],76.9115,43.25249,{"lat":43,"lon":42},[46],{"name":47,"role":11,"phone":48,"phoneExt":7,"email":49},"Marat Shoranov","+7(727)338-70-90","info@kaznmu.kz",{"facility":51,"status":21,"city":52,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":53,"geoPoint":57,"contacts":58},"State-owned public enterprise with the right of economic management \"Multidisciplinary City Hospital No. 1\" of the Akimat of Astana","Astana",{"type":26,"coordinates":54},[55,56],71.44598,51.1801,{"lat":56,"lon":55},[59],{"name":60,"role":11,"phone":61,"phoneExt":7,"email":62},"Marat Abduov","+7(7172) 27 20 28","gb1-astana@mail.ru",{"facility":64,"status":21,"city":65,"state":7,"zip":7,"country":23,"countryCode":24,"cosmosGeoPoint":66,"geoPoint":70,"contacts":71},"State-owned public enterprise with the right of economic management \"Regional Clinical Hospital\" of the Health Department of the Turkestan Region","Shymkent",{"type":26,"coordinates":67},[68,69],69.60042,42.30988,{"lat":69,"lon":68},[72],{"name":73,"role":11,"phone":74,"phoneExt":7,"email":75},"Zhanbolat Dildabekov","+7 (7252) 53 78 99","gkkp-okb@mail.ru",{"type":77,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100556326","clinical-efficacy-of-ustekinumab-in-crohns-disease-100556326",false,"NCT06523647","Clinical Efficacy of Ustekinumab in Crohn's Disease","Clinical Efficacy of Ustekinumab in Crohn's Disease: an Observational Study With Retrospective and Prospective Components","Inclusion Criteria:\n\n* Patients aged 18 years and older;\n* Patients who were first prescribed Ustekinumab between January 1 and December 31, 2024\n* Patients who provided written informed consent to participate in the study\n\nExclusion Criteria:\n\n* Contraindications to the use of the drug Ustekinumab per the current instructions:\n\n  * Clinically significant active infection (active tuberculosis, active viral hepatitis);\n  * Pregnancy and lactation;\n  * A history of clinically significant, in the opinion of the investigator, psychiatric disorders that may interfere with the study procedures and compliance with the drug regimen;\n  * Ulcerative colitis;\n  * Malignant gastrointestinal diseases in history or at the time of inclusion in the study;\n  * Decompensated chronic diseases of the liver, kidneys, cardiovascular system, systemic vasculitis, diabetes mellitus;\n  * Abuse of alcohol or psychoactive drugs within 1 year before the start of this study (as reported by the patient);\n* Participation in an interventional clinical trial.","ALL","18 Years",{"count":88,"type":89},150,"ESTIMATED","OBSERVATIONAL","Clinical Efficacy of Ustekinumab in Crohn's Disease: an Observational Study With Retrospective and Prospective Components.",[93],"Crohn's Disease","2024-07-23",{"date":96,"type":97},"2024-07-26","ACTUAL",{"date":99,"type":97},"2023-06-27",{"date":101,"type":89},"2025-12",{"name":5,"class":6},4]